Drug intelligence / Profile preview

ERI-3206

Development stage: Preclinical
Lead developer: Tempest Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ERI-3206 (also referred to as TPST-3206) is a preclinical allogeneic CAR T-cell therapy targeting CD70, being developed in an oncology-focused cell therapy pipeline acquired by Tempest Therapeutics from Erigen and Factor Bioscience. It is designed as an allogeneic, or “off‑the‑shelf,” CD70-directed CAR T product candidate for the treatment of CD70-expressing malignancies, such as certain hematologic cancers and potentially solid tumors, though specific indications and clinical data have not yet been disclosed publicly.[3][8][10]

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on ERI-3206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERI-3206.

Explore the full profile